Geode Capital Management LLC Acquires 171,609 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Geode Capital Management LLC increased its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 4.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,331,314 shares of the biopharmaceutical company’s stock after buying an additional 171,609 shares during the period. Geode Capital Management LLC owned 2.20% of Esperion Therapeutics worth $7,148,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Barclays PLC lifted its position in shares of Esperion Therapeutics by 99.6% during the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 154,509 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at $606,000. Anson Funds Management LP purchased a new stake in Esperion Therapeutics during the 3rd quarter worth about $540,000. Wellington Management Group LLP boosted its stake in Esperion Therapeutics by 66.8% in the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after purchasing an additional 241,512 shares during the period. Finally, State Street Corp grew its holdings in Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after buying an additional 99,802 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ESPR has been the subject of a number of analyst reports. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Esperion Therapeutics presently has an average rating of “Hold” and a consensus price target of $7.30.

Esperion Therapeutics Trading Down 0.5 %

ESPR opened at $2.19 on Friday. The stock has a market capitalization of $431.51 million, a P/E ratio of -3.42 and a beta of 1.01. The stock has a 50-day moving average price of $2.45 and a 200-day moving average price of $2.19. Esperion Therapeutics, Inc. has a 12-month low of $1.58 and a 12-month high of $3.94.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.